Covalent Fragment Screening (MS-Based) Service

Fragment-based drug discovery (FBLD) has become a cornerstone of modern pharmaceutical research, particularly when confronting targets that lack deep, well-defined binding pockets. By exploring chemical space with low-molecular-weight molecules (typically<300 Da), researchers can identify highly efficient starting points for drug development. However, developing covalent fragments—designed to form an irreversible or reversible permanent bond with a target amino acid residue—presents immense analytical challenges that traditional screening methods struggle to resolve.

Standard biophysical techniques, such as Thermal Shift Assays (TSA) or Surface Plasmon Resonance (SPR), provide indirect evidence of binding. While historically useful, these methods are notorious for generating high false-positive rates when dealing with covalent binders. At the high concentrations required for fragment screening (often in the millimolar range), compounds may cause a thermal shift simply by non-specifically aggregating on the protein surface, rather than forming a true, functional covalent bond. Conversely, specific but structurally subtle covalent binders might be missed entirely (false negatives) if their binding does not induce a substantial change in the target protein's global thermodynamic stability.

Mass spectrometry (MS) revolutionizes this process by offering a direct, label-free readout of the binding event. By measuring the exact monoisotopic mass of the target protein before and after incubation with a fragment library, we can observe the precise "mass shift" (+ΔMass) that occurs exclusively when a covalent bond is formed. This approach eliminates the reliance on reporter dyes, complex assay development, or indirect stability measurements, providing a definitive, evidence-based path forward for medicinal chemists.

In modern drug discovery, data is only as valuable as its transparency and interpretability. We adhere to a strict "white box" delivery model, ensuring that your medicinal chemists and structural biologists have full access to the primary analytical evidence supporting every identified hit.

• Intact MS Mass Shift Overlays: We provide clear visual overlays comparing the mass spectrum of the unliganded control protein directly against the spectrum of the fragment-incubated sample. This offers unambiguous, label-free confirmation of covalent adduct formation (+ΔMass).
• Deconvolution Hit Tables: You will receive a structured, easily sortable database of all screened fragments. This table scores fragments based on their specific binding efficiency and explicitly highlights our filtering process that removes multi-adduct (over-labeled) false positives.
• Peptide Mapping MS2 Spectra: For structurally confirmed hits, we provide deeply annotated MS2 fragmentation spectra. These high-resolution outputs pinpoint the exact modified amino acid residue, providing the structural rationale essential for subsequent covalent inhibitor profiling and lead optimization.

Direct observation of covalent mass shifts and site-specific peptide mapping.

The true bottleneck of high-throughput MS screening often lies not in the data acquisition, but in the complex data analysis. When screening "pools" of compounds, the resulting intact mass spectra contain hundreds of overlapping isotopic envelopes and charge states. Our bioinformatics team utilizes advanced Maximum Entropy deconvolution algorithms designed specifically for intact protein MS.

These advanced computational tools allow us to:

• Extract High-Resolution Zero-Charge Masses: We convert complex multi-charged m/z (mass-to-charge) spectra into clear, readable zero-charge molecular weights, resolving mass differences as small as a few Daltons even on proteins exceeding 50 kDa.
• Automated Delta-Mass Match-Making: Our software automatically calculates the mass shifts and cross-references them against the specific chemical structures and expected monoisotopic masses provided in your fragment library.
• Rigorous Artifact Mitigation: By analyzing the peak intensity distributions, we can statistically differentiate true covalent binding from baseline noise, salt adduct artifacts, or non-covalent carryover, ensuring the highest possible confidence in the final hit selection.

If your team requires validation of hit selectivity in a cellular context post-screening, we seamlessly transition these hits into our comprehensive chemoproteomics services to assess proteome-wide off-target liabilities.

Choosing the optimal primary screen is a strategic decision that heavily impacts the cost, speed, and success rate of your discovery timeline. Use the following comparative analysis to understand why intact mass spectrometry is rapidly becoming the preferred primary screening tool for covalent FBLD.

To guarantee the success and sensitivity of your screening campaign, we enforce strict guidelines for target protein preparation and library submission. Should your project require screening of non-covalent interactions alongside covalent ones, our Affinity Selection Mass Spectrometry (ASMS) platform is available as a complementary workflow.